Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Ixazomib

Release date: 2024-07-10 15:20:34     Recommended: 132

10L1026_23 伊沙佐米 批文_00.jpg

Isazomi is an oral, highly selective proteasome inhibitor, and NINLARO is a proteasome inhibitor suitable for use in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one previous treatment.

Company News

Research News

Drug news